Skip to main content
| News

Celonic agrees cooperation to combat coronavirus

26.05.2020

The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.

SARS-CoV-2

The core element of the collaboration between Airway Therapeutics and Celonic is based on the novel human recombinant protein AT-100. Airway Therapeutics has developed this protein on the basis of genetic engineering. Up to now, it has shown “great potential” in fighting inflammation and serious respiratory diseases driven by infection, as detailed by Marc Salzberg, CEO of Airway Therapeutics, in a press release issued by the two firms. However, the protein has so far not been manufactured in the volumes required for clinical trials. The Basel-based Celonic Group will now be responsible for this task.

“Given the urgency of the current pandemic, I am thrilled to establish this collaboration with Celonic, a leader in biologic manufacturing”, Salzberg states. Celonic will optimize manufacturing processes within the framework of this cooperation and assume responsibility for ensuring that production processes comply with the applicable guidelines for pharmaceuticals and active substances in the requisite volume for a clinical trial. Production is to begin as early as June 2020.

At Celonic, the prevailing sentiments are of excitement and pride in the cooperation with Airway and in taking part in the fight against this global pandemic, according to Konstantin Matentzoglu, CEO of Celonic, who was quoted in the press release. “AT-100 has the potential to be a lifesaving treatment for COVID-19 patients until a vaccine is available”, he comments. Seriously ill patients and those in intensive care stand to primarily benefit from this development.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Invest

How Moderna is growing in Switzerland

The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sandoz decides on Basel for headquarters

Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...

Read More
VectivBio sold for approximately 1 billion dollars
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio sold for approximately 1 billion dollars

The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

University of Basel and RocketVax present new Covid vaccine

Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest

Rami Swiss and Elbit Systems now manufacturing in Jura

The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel to become Europe’s Silicon Valley of biotech

Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....

Read More
1 2 3 63

Do you have a question? We'd like to hear from you.